10,576 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Bought by Garrison Point Advisors LLC

Garrison Point Advisors LLC bought a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,576 shares of the biopharmaceutical company’s stock, valued at approximately $163,000.

Other large investors have also recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. increased its position in shares of ACADIA Pharmaceuticals by 24.2% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 142,998 shares of the biopharmaceutical company’s stock worth $2,644,000 after purchasing an additional 27,871 shares during the last quarter. Diversified Trust Co raised its position in ACADIA Pharmaceuticals by 6.3% during the first quarter. Diversified Trust Co now owns 30,865 shares of the biopharmaceutical company’s stock worth $571,000 after acquiring an additional 1,826 shares in the last quarter. Privium Fund Management B.V. acquired a new stake in ACADIA Pharmaceuticals in the first quarter valued at $2,744,000. Capstone Investment Advisors LLC acquired a new stake in ACADIA Pharmaceuticals in the first quarter valued at $211,000. Finally, GSA Capital Partners LLP grew its position in shares of ACADIA Pharmaceuticals by 730.9% in the 1st quarter. GSA Capital Partners LLP now owns 111,394 shares of the biopharmaceutical company’s stock valued at $2,060,000 after acquiring an additional 97,987 shares during the period. Institutional investors own 96.71% of the company’s stock.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 9,534 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $145,679.52. Following the sale, the chief operating officer now directly owns 52,177 shares of the company’s stock, valued at $797,264.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 9,733 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $148,720.24. Following the completion of the sale, the chief financial officer now owns 43,735 shares of the company’s stock, valued at approximately $668,270.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Brendan Teehan sold 9,534 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $145,679.52. Following the transaction, the chief operating officer now owns 52,177 shares of the company’s stock, valued at approximately $797,264.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,014 shares of company stock worth $779,494. Corporate insiders own 28.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ACAD shares. Citigroup cut their price objective on ACADIA Pharmaceuticals from $30.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, August 8th. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, September 13th. Royal Bank of Canada cut their target price on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Finally, Raymond James reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. Six investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $25.56.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD opened at $14.48 on Friday. ACADIA Pharmaceuticals Inc. has a 52-week low of $14.15 and a 52-week high of $32.59. The firm has a market cap of $2.39 billion, a price-to-earnings ratio of -1,448.00, a PEG ratio of 0.49 and a beta of 0.38. The business’s fifty day moving average is $15.58 and its 200-day moving average is $16.13.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.18 by $0.02. The firm had revenue of $241.96 million during the quarter, compared to the consensus estimate of $235.95 million. ACADIA Pharmaceuticals had a return on equity of 6.89% and a net margin of 3.43%. The business’s quarterly revenue was up 46.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.01 earnings per share. As a group, research analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.52 EPS for the current fiscal year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.